Identification

Name
Triamcinolone
Accession Number
DB00620  (APRD00422)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739)

Structure
Thumb
Synonyms
  • 11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
  • 9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
  • 9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
  • 9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
  • 9α-fluoro-16α-hydroxyprednisolone
  • Fluoxyprednisolone
  • Tiamcinolonum
  • Triamcinolona
  • Triamcinolonum
Product Ingredients
IngredientUNIICASInChI Key
Triamcinolone acetonideF446C597KA76-25-5YNDXUCZADRHECN-JNQJZLCISA-N
Triamcinolone diacetateA73MM2Q32P67-78-7XGMPVBXKDAHORN-RBWIMXSLSA-N
Triamcinolone hexacetonideI7GT1U99Y95611-51-8TZIZWYVVGLXXFV-FLRHRWPCSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AllerNazeSpray, metered.5 mg/mLNasalLupin Pharmaceuticals2011-02-01Not applicableUs
Aristocort - Syr Orl 0.4mg/mlSyrup.4 mgOralGlades, Division Of Stiefel Canada Inc.1996-10-101997-08-05Canada
Aristocort - Tab 4mgTablet4 mgOralGlades, Division Of Stiefel Canada Inc.1998-05-112004-01-27Canada
Aristocort CCream0.5 %TopicalValeant Canada Lp Valeant Canada S.E.C.1997-10-21Not applicableCanada
Aristocort C Crm 0.5%Cream5 mgTopicalLederle Cyanamid Canada Inc.1965-12-311997-08-14Canada
Aristocort D - Crm Top 0.025%Cream.025 %TopicalGlades, Division Of Stiefel Canada Inc.1996-10-101998-07-09Canada
Aristocort D Crm 0.025%Cream.25 mgTopicalLederle Cyanamid Canada Inc.1974-12-311997-01-29Canada
Aristocort Forte - Liq Ia Im Isy 40mg/mlLiquid40 mgIntra-articular; Intramuscular; IntrasynovialGlades, Division Of Stiefel Canada Inc.1996-12-062000-12-04Canada
Aristocort Forte Inj 40mg/mlLiquid40 mgIntra-articular; Intramuscular; IntrasynovialLederle Cyanamid Canada Inc.1962-12-311997-01-29Canada
Aristocort Inj Intralesional 25mg/mlLiquid25 mgIntra-articular; Intradermal; IntramuscularLederle Cyanamid Canada Inc.1962-12-311997-01-29Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-triamcinolone AQSpray, metered55 mcgNasalApotex Corporation2016-06-15Not applicableCanada
DermacinRx Silazone PakKitPure Tek Corporation2015-12-10Not applicableUs
DermacinRx TrizapakKitPure Tek Corporation2016-08-022017-08-24Us
Dermasorb TA Complete KitKitCrown Laboratories2013-11-14Not applicableUs
DermazoneKitShoreline Pharmaceuticals, Inc.2016-04-20Not applicableUs
Juulissa PharmapakKitPure Tek Corporation2016-12-28Not applicableUs
OralonePaste1 mg/gDentalTaro Pharmaceuticals U.S.A., Inc.1986-10-01Not applicableUs
Pediaderm TAKitArbor Pharmaceuticals2011-01-01Not applicableUs
Pediaderm TACream1 mg/gTopicalArbor Pharmaceuticals2010-09-01Not applicableUs
SilaLite PakKitShoreline Pharmaceuticals, Inc.2016-12-05Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
24 Hour Nasal AllergySpray, metered55 ug/1NasalKroger2016-04-10Not applicableUs
24 Hour Nasal AllergySpray, metered55 ug/1NasalMeijer Distribution2017-01-18Not applicableUs
Allergy NasalSpray, metered55 ug/1NasalWalgreen2016-04-10Not applicableUs
CareOne Allergy ReliefSpray, metered55 ug/1NasalAmerican Sales Company2017-06-12Not applicableUs
Childrens Nasacort Allergy 24HRSpray, metered55 ug/1NasalChattem, Inc.2015-07-01Not applicableUs
Equaline nasal allergySpray, metered55 ug/1NasalSupervalu2016-12-29Not applicableUs
Equate Nasal AllergySpray, metered55 ug/1NasalWalmart Stores2016-04-17Not applicableUs
Good Neighbor Pharmacy 24 Hour Nasal AllergySpray, metered55 ug/1NasalAmerisource Bergen2016-10-24Not applicableUs
Good Sense Nasal AllergySpray, metered55 ug/1NasalL. Perrigo Company2017-02-09Not applicableUs
Harris Teeter Nasal AllergySpray, metered55 ug/1NasalHarris Teeter2017-01-18Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Triamcinolone AcetonidePaste1 mg/gDentalPreferreed Pharmaceuticals Inc.2017-10-31Not applicableUs
Triamcinolone AcetonideCream.25 mg/gTopicalPreferreed Pharmaceuticals Inc.2017-11-01Not applicableUs
Triamcinolone AcetonideOintment5 mg/gTopicalGw Pharmaceuticals Ltd.2017-10-31Not applicableUs
Triloan II SUIKInjection, suspension40 mg/mLIntra-articular; IntramuscularAsclemed Usa, Inc.2009-06-01Not applicableUs
Triloan SUIKInjection, suspension40 mg/mLIntra-articular; IntramuscularAsclemed Usa, Inc.2009-06-01Not applicableUs
International/Other Brands
Aristocort / Delphicort / Flutex / Kenacort / Omcilon-A / Oracort / Tri-Nasal / Triacet / Triacort / Triaderm / Tricortone / Trilone / Tristoject
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aristoform R Crm 0.1%Triamcinolone acetonide (1 mg) + Clioquinol (30 mg)CreamTopicalLederle Cyanamid Canada Inc.1966-12-311997-01-29Canada
Kenacomb CreamTriamcinolone acetonide (1 mg) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Nystatin (100000 unit)CreamTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1965-12-312004-08-05Canada
Kenacomb Mild CreamTriamcinolone acetonide (.25 mg) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Nystatin (100000 unit)CreamTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1968-12-312004-08-05Canada
Kenacomb Mild OintmentTriamcinolone acetonide (.25 mg) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Nystatin (100000 unit)OintmentTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1968-12-312004-08-05Canada
Kenacomb OintmentTriamcinolone acetonide (1 mg) + Gramicidin D (.25 mg) + Neomycin sulfate (2.5 mg) + Nystatin (100000 unit)OintmentTopicalWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.1996-07-312004-08-05Canada
Kenacomb OntTriamcinolone acetonide (1 mg) + Gramicidin D (.25 mg) + Neomycin (2.5 mg) + Nystatin (100000 unit)OintmentTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1965-12-311997-08-14Canada
Mecomb Crm 0.1%Triamcinolone acetonide (1 mg) + Gramicidin D (.25 mg) + Neomycin (2.5 mg) + Nystatin (100000 unit)CreamTopicalMedic Laboratory LtÉe1979-12-312003-07-17Canada
Nystatin and TriamcinoloneTriamcinolone acetonide (1 mg/g) + Nystatin (100000 [USP'U]/g)OintmentTopicalPhysicians Total Care, Inc.2005-03-03Not applicableUs
Nystatin and TriamcinoloneTriamcinolone acetonide (1 mg/g) + Nystatin (100000 U/g)CreamTopicalSTAT RX LLC USA1987-12-22Not applicableUs
Nystatin and TriamcinoloneTriamcinolone acetonide (1 mg/g) + Nystatin (100000 [USP'U]/g)CreamTopicalRebel Distributors1987-12-22Not applicableUs
Categories
UNII
1ZK20VI6TY
CAS number
124-94-7
Weight
Average: 394.4339
Monoisotopic: 394.179166801
Chemical Formula
C21H27FO6
InChI Key
GFNANZIMVAIWHM-OBYCQNJPSA-N
InChI
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13R,14S,15S,17S)-1-fluoro-13,14,17-trihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES

Pharmacology

Indication

For the treatment of perennial and seasonal allergic rhinitis.

Structured Indications
Pharmacodynamics

Triamcinolone and its derivatives are synthetic glucocorticoids that are used for their antiinflammatory or immunosuppressive properties.

Mechanism of action

The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors which translocate into the nucleus and bind DNA (GRE) and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Rapid absorption following oral administration

Volume of distribution
Not Available
Protein binding

68%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

88 minutes

Clearance
Not Available
Toxicity

LD50=>500mg/kg (in rats)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Triamcinolone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Triamcinolone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Triamcinolone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Triamcinolone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triamcinolone.Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Triamcinolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Triamcinolone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Triamcinolone.Experimental, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Triamcinolone.Approved, Withdrawn
AldesleukinTriamcinolone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Triamcinolone can be decreased when combined with Algeldrate.Approved, Experimental
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Triamcinolone.Investigational
AlmagateThe bioavailability of Triamcinolone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Triamcinolone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Triamcinolone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triamcinolone.Approved
AloglutamolThe bioavailability of Triamcinolone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Triamcinolone.Experimental
AluminiumThe bioavailability of Triamcinolone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Triamcinolone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Triamcinolone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Triamcinolone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Triamcinolone.Approved
AmiodaroneThe metabolism of Triamcinolone can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BTriamcinolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Triamcinolone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Triamcinolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Triamcinolone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Triamcinolone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Triamcinolone.Approved, Investigational
AprepitantThe serum concentration of Triamcinolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Triamcinolone can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Triamcinolone can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Triamcinolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Triamcinolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Triamcinolone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Triamcinolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Triamcinolone.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Triamcinolone.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Triamcinolone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Triamcinolone.Experimental
BendroflumethiazideTriamcinolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Triamcinolone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Triamcinolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Triamcinolone.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Triamcinolone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Triamcinolone.Experimental
Bismuth SubcitrateThe bioavailability of Triamcinolone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Triamcinolone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Triamcinolone can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Triamcinolone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Triamcinolone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Triamcinolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Triamcinolone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Triamcinolone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Triamcinolone.Investigational, Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Triamcinolone.Experimental
BumetanideTriamcinolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Triamcinolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Triamcinolone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Triamcinolone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triamcinolone.Approved
Capromab pendetideTriamcinolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Triamcinolone can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Triamcinolone.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Triamcinolone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Triamcinolone.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triamcinolone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Triamcinolone.Approved, Investigational
CeritinibThe serum concentration of Triamcinolone can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Triamcinolone.Approved, Vet Approved
ChlorothiazideTriamcinolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Triamcinolone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triamcinolone.Approved
ChlorthalidoneTriamcinolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Triamcinolone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triamcinolone.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Triamcinolone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Triamcinolone can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Triamcinolone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Triamcinolone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotrimazoleThe metabolism of Triamcinolone can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Triamcinolone can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Triamcinolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Triamcinolone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Triamcinolone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Triamcinolone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Triamcinolone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Triamcinolone can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Triamcinolone.Investigational
CyclopenthiazideTriamcinolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Triamcinolone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Triamcinolone.Investigational
DabrafenibThe serum concentration of Triamcinolone can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Triamcinolone can be increased when it is combined with Daidzein.Experimental
DanazolTriamcinolone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe metabolism of Triamcinolone can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Triamcinolone can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Triamcinolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Triamcinolone can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Triamcinolone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Triamcinolone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Triamcinolone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Triamcinolone.Approved, Vet Approved
DienestrolThe serum concentration of Triamcinolone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Triamcinolone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Triamcinolone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triamcinolone.Approved
DihydroergotamineThe metabolism of Triamcinolone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneTriamcinolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Triamcinolone can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Donepezil.Approved
DoxycyclineThe metabolism of Triamcinolone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Triamcinolone can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Triamcinolone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triamcinolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Triamcinolone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Triamcinolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Edrophonium.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triamcinolone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Triamcinolone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Triamcinolone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Triamcinolone.Approved
EquolThe serum concentration of Triamcinolone can be increased when it is combined with Equol.Investigational
ErythromycinThe metabolism of Triamcinolone can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Triamcinolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Triamcinolone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Triamcinolone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Triamcinolone can be increased when it is combined with Estrone.Approved
Etacrynic acidTriamcinolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Triamcinolone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Triamcinolone.Experimental
Ethinyl EstradiolThe serum concentration of Triamcinolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Triamcinolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Triamcinolone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Triamcinolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Triamcinolone.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Triamcinolone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Triamcinolone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Triamcinolone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Triamcinolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Triamcinolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Triamcinolone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Triamcinolone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Triamcinolone.Experimental
FingolimodTriamcinolone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Triamcinolone.Approved, Withdrawn
FluconazoleThe metabolism of Triamcinolone can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Triamcinolone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Triamcinolone.Experimental
FluoxymesteroneTriamcinolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Triamcinolone.Approved, Investigational
FluvoxamineThe metabolism of Triamcinolone can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Triamcinolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Triamcinolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Triamcinolone can be increased when combined with Fosphenytoin.Approved
FurosemideTriamcinolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Triamcinolone can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Triamcinolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Triamcinolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Triamcinolone is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Triamcinolone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Triamcinolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Triamcinolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triamcinolone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triamcinolone.Approved, Investigational
GLPG-0492Triamcinolone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Triamcinolone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Triamcinolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Triamcinolone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Triamcinolone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Triamcinolone.Experimental
HexestrolThe serum concentration of Triamcinolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Triamcinolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.Approved, Investigational
HydrochlorothiazideTriamcinolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideTriamcinolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Triamcinolone can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Triamcinolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Triamcinolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Triamcinolone.Approved
IdelalisibThe serum concentration of Triamcinolone can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Triamcinolone can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Triamcinolone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Triamcinolone.Approved
IndapamideTriamcinolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Triamcinolone can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Triamcinolone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Triamcinolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Triamcinolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Triamcinolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Triamcinolone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Triamcinolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Triamcinolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triamcinolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Triamcinolone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Triamcinolone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triamcinolone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triamcinolone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Triamcinolone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Triamcinolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Triamcinolone.Withdrawn
IsradipineThe metabolism of Triamcinolone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Triamcinolone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Triamcinolone can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Triamcinolone.Experimental
KetoconazoleThe metabolism of Triamcinolone can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Triamcinolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Triamcinolone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Triamcinolone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Triamcinolone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Triamcinolone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Triamcinolone.Experimental
LopinavirThe metabolism of Triamcinolone can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Triamcinolone.Approved, Investigational
LovastatinThe metabolism of Triamcinolone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Triamcinolone.Approved, Investigational
LuliconazoleThe serum concentration of Triamcinolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Triamcinolone can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Triamcinolone.Approved, Investigational
MagaldrateThe bioavailability of Triamcinolone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Triamcinolone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Triamcinolone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Triamcinolone.Approved
Magnesium silicateThe bioavailability of Triamcinolone can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Triamcinolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Triamcinolone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Triamcinolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Triamcinolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Triamcinolone.Approved
MesteroloneTriamcinolone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Triamcinolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Triamcinolone.Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Triamcinolone.Approved
MethallenestrilThe serum concentration of Triamcinolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideTriamcinolone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Triamcinolone.Approved, Vet Approved
MethyltestosteroneTriamcinolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Metoclopramide.Approved, Investigational
MetolazoneTriamcinolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe serum concentration of Triamcinolone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Triamcinolone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Triamcinolone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Triamcinolone.Approved, Investigational
MitotaneThe serum concentration of Triamcinolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Triamcinolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Triamcinolone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Triamcinolone.Experimental
MoxestrolThe serum concentration of Triamcinolone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Triamcinolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Triamcinolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Triamcinolone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Triamcinolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nalidixic Acid.Approved, Investigational
NandroloneTriamcinolone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateTriamcinolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Triamcinolone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Triamcinolone.Approved, Investigational
NefazodoneThe metabolism of Triamcinolone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Triamcinolone can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Triamcinolone.Approved
NetupitantThe serum concentration of Triamcinolone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Triamcinolone can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Triamcinolone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Triamcinolone.Approved
NilotinibThe metabolism of Triamcinolone can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Triamcinolone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Triamcinolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Norfloxacin.Approved
OlaparibThe metabolism of Triamcinolone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triamcinolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Triamcinolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Triamcinolone.Vet Approved
OsimertinibThe serum concentration of Triamcinolone can be increased when it is combined with Osimertinib.Approved
OxandroloneTriamcinolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Triamcinolone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Oxolinic acid.Experimental
OxymetholoneTriamcinolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Triamcinolone.Approved, Withdrawn
PalbociclibThe serum concentration of Triamcinolone can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Triamcinolone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Triamcinolone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Triamcinolone can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Triamcinolone.Approved, Investigational, Withdrawn
PhenobarbitalThe metabolism of Triamcinolone can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Triamcinolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Triamcinolone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Triamcinolone.Approved, Investigational
PhenytoinThe metabolism of Triamcinolone can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Triamcinolone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triamcinolone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pipemidic acid.Experimental
PiretanideTriamcinolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Triamcinolone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triamcinolone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Triamcinolone.Experimental
Polyestradiol phosphateThe serum concentration of Triamcinolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideTriamcinolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Triamcinolone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Triamcinolone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Triamcinolone.Experimental, Investigational
PrimidoneThe metabolism of Triamcinolone can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Triamcinolone.Experimental
PromestrieneThe serum concentration of Triamcinolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Triamcinolone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Triamcinolone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Triamcinolone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Triamcinolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Triamcinolone can be increased when it is combined with Quinestrol.Approved
QuinethazoneTriamcinolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Triamcinolone.Approved
RanolazineThe metabolism of Triamcinolone can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Triamcinolone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Triamcinolone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Triamcinolone.Approved, Experimental, Investigational
RifabutinThe metabolism of Triamcinolone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Triamcinolone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Triamcinolone can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rindopepimut.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Ritonavir is combined with Triamcinolone.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Triamcinolone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Triamcinolone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triamcinolone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triamcinolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Triamcinolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Triamcinolone.Approved
SaquinavirThe metabolism of Triamcinolone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Triamcinolone.Approved
SecoisolariciresinolThe serum concentration of Triamcinolone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Triamcinolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Triamcinolone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Triamcinolone.Investigational
SildenafilThe metabolism of Triamcinolone can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Triamcinolone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Triamcinolone can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Triamcinolone.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triamcinolone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Triamcinolone can be decreased when combined with Sodium bicarbonate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Triamcinolone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Triamcinolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Triamcinolone.Investigational
St. John's WortThe serum concentration of Triamcinolone can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololTriamcinolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Triamcinolone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Triamcinolone.Approved
SulfisoxazoleThe metabolism of Triamcinolone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Triamcinolone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triamcinolone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Triamcinolone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Triamcinolone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Triamcinolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Triamcinolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Triamcinolone.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Triamcinolone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Triamcinolone.Approved, Withdrawn
TelithromycinThe metabolism of Triamcinolone can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Triamcinolone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Triamcinolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Triamcinolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Triamcinolone.Approved
TestosteroneTriamcinolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateTriamcinolone may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The risk or severity of adverse effects can be increased when Triamcinolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Triamcinolone.Approved
TiboloneThe serum concentration of Triamcinolone can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Triamcinolone can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Triamcinolone.Investigational
TocilizumabThe serum concentration of Triamcinolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTriamcinolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triamcinolone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triamcinolone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Triamcinolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Triamcinolone.Approved
TorasemideTriamcinolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Triamcinolone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Triamcinolone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Triamcinolone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Trichlorfon.Vet Approved
TrichlormethiazideTriamcinolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Triamcinolone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Triamcinolone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Triamcinolone.Approved
TromethamineThe bioavailability of Triamcinolone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Triamcinolone.Investigational, Withdrawn
VenlafaxineThe metabolism of Triamcinolone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Triamcinolone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triamcinolone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Triamcinolone.Approved, Investigational
VoriconazoleThe metabolism of Triamcinolone can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinTriamcinolone may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Triamcinolone.Approved, Investigational
ZeranolThe serum concentration of Triamcinolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Triamcinolone.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Triamcinolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Triamcinolone.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Abu Alam, "Triamcinolone formulations and methods for their preparation and use." U.S. Patent US20040186084, issued September 23, 2004.

US20040186084
General References
Not Available
External Links
Human Metabolome Database
HMDB14758
KEGG Drug
D00385
PubChem Compound
31307
PubChem Substance
46507950
ChemSpider
29046
BindingDB
41132
ChEBI
9667
ChEMBL
CHEMBL1451
Therapeutic Targets Database
DAP000417
PharmGKB
PA451749
IUPHAR
2870
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Triamcinolone
ATC Codes
R01AD11 — TriamcinoloneS02CA04 — Triamcinolone and antiinfectivesC05AA12 — TriamcinoloneD07CB01 — Triamcinolone and antibioticsD07BB03 — Triamcinolone and antisepticsH02AB08 — TriamcinoloneD07AB09 — TriamcinoloneS01BA05 — TriamcinoloneR03BA06 — TriamcinoloneA01AC01 — TriamcinoloneD07XB02 — Triamcinolone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (150 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedDiagnosticRetinopathy, Diabetic1
0Unknown StatusTreatmentGreater Trochanteric Pain Syndrome1
1CompletedTreatmentDiabetic Macular Edema (DME)1
1CompletedTreatmentMacular Degeneration / Retinal Vein Occlusions(RVO)1
1CompletedTreatmentMacular Degeneration / Retinal Vein Occlusions(RVO) / Retinopathy, Diabetic1
1RecruitingTreatmentCystoid Macular Edema1
1TerminatedDiagnosticFibrosis1
1TerminatedTreatmentRotator Cuff Syndrome1
1Unknown StatusTreatmentCystoid Macular Edema / Uveitis1
1Unknown StatusTreatmentDiabetic Macular Edema (DME) / Retinopathy, Diabetic1
1, 2CompletedSupportive CareMucositis1
1, 2CompletedTreatmentAge-Related Macular Degeneration (ARMD) / Subfoveal Choroidal Neovascularization1
1, 2CompletedTreatmentDiabetic Macular Edema (DME)1
1, 2CompletedTreatmentDiffuse posterior uveitis / Noninfectious Uveitis / Panuveitis / Uveitis / Uveitis, Intermediate1
1, 2Unknown StatusTreatmentAcute Nonarteritic Anterior Ischemic Optic Neuropathy1
1, 2Unknown StatusTreatmentDiabetic Macular Edema (DME)1
1, 2Unknown StatusTreatmentRetinopathy, Diabetic2
2Active Not RecruitingTreatmentDiabetic Macular Edema (DME)1
2CompletedBasic ScienceDiabetic Macular Edema (DME)1
2CompletedDiagnosticKnee Osteoarthritis (Knee OA) / Type 2 Diabetes Mellitus1
2CompletedScreeningAlopecia Areata (AA)1
2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
2CompletedTreatmentAnterior Cruciate Ligament (ACL) Tears1
2CompletedTreatmentAtopic Dermatitis (AD)1
2CompletedTreatmentBranch Retinal Vein Occlusion1
2CompletedTreatmentDiabetic Macular Edema (DME)3
2CompletedTreatmentGout Acute1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2CompletedTreatmentNon-Melanomatous Skin Cancer / Precancerous/Nonmalignant Condition1
2CompletedTreatmentOral Lichen Planus1
2Not Yet RecruitingTreatmentErosive Oral Lichen Planus1
2RecruitingNot AvailablePain1
2RecruitingPreventionAcneiform Rash / Papulopustular Eruption1
2RecruitingTreatmentAbdominal Pain (AP)1
2RecruitingTreatmentAcute Gouty Arthritis1
2RecruitingTreatmentAtopic Dermatitis (AD)1
2RecruitingTreatmentInterstitial Cystitis / Painful Bladder Syndrome (PBS)1
2RecruitingTreatmentVitiligo1
2TerminatedTreatmentMacular Edema (ME)1
2TerminatedTreatmentPolyps, Nasal1
2TerminatedTreatmentPost-traumatic Osteoarthritis of the Knee1
2Unknown StatusTreatmentBranch Retinal Vein Occlusion1
2Unknown StatusTreatmentCentral Retinal Vein Occlusion (CRVO)1
2Unknown StatusTreatmentRetinopathy, Diabetic1
2Unknown StatusTreatmentRetinovascular Disease1
2Unknown StatusTreatmentShoulder Pain2
2Unknown StatusTreatmentWet Macular Degeneration1
2WithdrawnTreatmentMacular Edema (ME) / Uveitis1
2, 3CompletedTreatmentGlaucoma1
2, 3CompletedTreatmentMacular Edema (ME)1
2, 3Not Yet RecruitingTreatmentCarpal Tunnel Syndrome (CTS)1
2, 3RecruitingTreatmentKnee Arthritis1
2, 3RecruitingTreatmentProliferative Diabetic Retinopathy (PDR)1
2, 3RecruitingTreatmentTrigger Digit1
2, 3RecruitingTreatmentVitiligo1
2, 3SuspendedTreatmentMelasma1
2, 3Unknown StatusTreatmentAge-Related Macular Degeneration (ARMD)1
2, 3Unknown StatusTreatmentUveal Melanoma1
3Active Not RecruitingTreatmentAdhesive Capsulitis of Shoulder / Shoulder Adhesive Capsulitis / Shoulder Capsulitis1
3Active Not RecruitingTreatmentAnterior Uveitis (AU) / Diffuse posterior uveitis / Panuveitis / Uveitis / Uveitis, Intermediate2
3Active Not RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
3CompletedPreventionCataracts / Cystoid Macular Edema / Diabetes Mellitus (DM)1
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentChronic Lung Diseases / Chronic Obstructive Pulmonary Disease (COPD) / Lung Diseases, Obstructive1
3CompletedTreatmentDiabetic Macular Edema (DME) / DME / Retinopathy, Diabetic1
3CompletedTreatmentDiabetic Macular Edema (DME)1
3CompletedTreatmentDiabetic Macular Edema (DME) / Proliferative Diabetic Retinopathy (PDR)1
3CompletedTreatmentDupuytren's Contracture1
3CompletedTreatmentGout Acute2
3CompletedTreatmentKnee Osteoarthritis (Knee OA)1
3CompletedTreatmentMacular Degeneration1
3CompletedTreatmentMacular Degeneration / Subfoveal Choroidal Neovascularization1
3CompletedTreatmentMacular Edema (ME) / Macular Edema, Cystoid / Retinal Vein Occlusions(RVO)1
3CompletedTreatmentMacular Edema (ME) / Retinopathy, Diabetic1
3CompletedTreatmentNegative Middle Ear Pressure / Otitis Media, Serous / Rhinitis1
3CompletedTreatmentOral Lichen Planus1
3CompletedTreatmentOral Pemphigus Vulgaris1
3CompletedTreatmentOsteoarthritis (OA)1
3CompletedTreatmentPancreatitis, Chronic1
3CompletedTreatmentRadicular syndrome1
3CompletedTreatmentRetinal Vein Occlusions(RVO)1
3CompletedTreatmentRhinitis, Allergic, Perennial1
3CompletedTreatmentSeasonal Allergic Rhinitis (SAR)1
3CompletedTreatmentVitrectomy therapy1
3CompletedTreatmentVitreoretinopathy, Proliferative1
3Not Yet RecruitingTreatmentOptic Neuropathy, Ischemic / Triamcinolone Acetonide1
3RecruitingPreventionProliferative Diabetic Retinopathy (PDR)1
3RecruitingTreatmentChalazion1
3RecruitingTreatmentEye Injury Trauma1
3RecruitingTreatmentInflammatory Macular Edema1
3RecruitingTreatmentKeloid Scars1
3RecruitingTreatmentLateral Epicondylitis1
3RecruitingTreatmentOther Abnormal Granulation Tissue Nos1
3TerminatedTreatmentAcute Gouty Arthritis1
3TerminatedTreatmentRhinitis1
3TerminatedTreatmentUveitis1
3Unknown StatusTreatmentDiabetic Macular Edema (DME)4
3Unknown StatusTreatmentDiffuse Diabetic Macular Edema1
4Active Not RecruitingTreatmentArthritis of the Knee1
4Active Not RecruitingTreatmentAtopic Dermatitis (AD)1
4Active Not RecruitingTreatmentExudative Retinal Detachment / Uveal Melanoma1
4CompletedBasic ScienceTo Assess the Changes in Bone Mineral Density / To Assess the Changes in Markers of Bone Turnover Over a Six Month Period After Epidural Steroid Inject1
4CompletedPreventionRetinal Detachment / Retinoschisis / Vitreoretinopathy, Proliferative1
4CompletedTreatmentAdrenal Insufficiency / Tendinopathy1
4CompletedTreatmentAtopic Dermatitis (AD)1
4CompletedTreatmentAtypical Facial Pain / Typical Facial Pain1
4CompletedTreatmentDiabetic Macular Edema (DME)2
4CompletedTreatmentEpicondylitis, Lateral Humeral / Lateral Epicondylitis1
4CompletedTreatmentFat Reduction1
4CompletedTreatmentImpingement Shoulder1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentOral Lichen Planus1
4CompletedTreatmentOsteoarthritis (OA)2
4CompletedTreatmentOsteoarthritis (OA) of the Knee1
4CompletedTreatmentSinusitis1
4Enrolling by InvitationTreatmentSacro-Iliac Spondylosis1
4Not Yet RecruitingOtherComplex Regional Pain Syndromes (CRPS) / Shoulder Hand Syndrome1
4Not Yet RecruitingTreatmentCystoid Macular Edema / Uveitis1
4Not Yet RecruitingTreatmentDiabetes Mellitus (DM) / Rotator Cuff Injury / Rotator Cuff Syndrome / Rotator Cuff Tendinitis1
4Not Yet RecruitingTreatmentFunctional Performance / Physical Activity1
4Not Yet RecruitingTreatmentHysterectomy1
4Not Yet RecruitingTreatmentPain / Strokes1
4RecruitingTreatmentAlopecia Areata (AA)1
4RecruitingTreatmentChoroidal Effusions / Glaucoma1
4RecruitingTreatmentHeadaches1
4RecruitingTreatmentHypergranulation Tissue; Gastrostomy Tube Site1
4RecruitingTreatmentInflammatory Reaction / Intraocular Pressure1
4RecruitingTreatmentKeloidscars1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)3
4RecruitingTreatmentLateral Epicondylitis1
4RecruitingTreatmentNasal Obstruction1
4RecruitingTreatmentShoulder Pain1
4RecruitingTreatmentWet Macular Degeneration1
4SuspendedTreatmentMacular Edema (ME) / Uveitis1
4SuspendedTreatmentPsoriasis1
4TerminatedTreatmentArthritis Multiple Joint / Basal Thumb Joint Arthritis / Basilar Joint Arthritis / Carpometacarpal Arthritis / Trapeziometacarpal Arthritis1
4Unknown StatusTreatmentCentral Retinal Vein Occlusion (CRVO) / Macular Edema (ME)1
4Unknown StatusTreatmentDermatitis, Contact / Dermatitis, Occupational1
4Unknown StatusTreatmentKeloid Scars1
4WithdrawnTreatmentAbdominal Cutaneous Nerve Entrapment Syndrome / Chronic Abdominal Wall Pain1
Not AvailableActive Not RecruitingNot AvailableOsteoarthritis Thumb1
Not AvailableActive Not RecruitingOtherAsthma Bronchial / Severe Persistent Asthma1
Not AvailableActive Not RecruitingTreatmentAcne1
Not AvailableActive Not RecruitingTreatmentCervial Disc Herniation / Cervical Disc Herniation / Prolapsed Lumbar Disc1
Not AvailableActive Not RecruitingTreatmentCervical Spine1
Not AvailableActive Not RecruitingTreatmentLumbosacral Spondylosis / Radicular syndrome / Spinal Stenosis1
Not AvailableCompletedNot AvailableMalignant Neoplasm of Pancreas / Pancreatitis, Chronic1
Not AvailableCompletedNot AvailablePain1
Not AvailableCompletedNot AvailableTrigger Finger1
Not AvailableCompletedBasic ScienceAcute Steroid Responsive Dermatoses / Chronic Steroid Responsive Dermatoses1
Not AvailableCompletedPreventionTracheal Intubation1
Not AvailableCompletedSupportive CareBlind Painful Eye / Control of Pain Through Drug Injection / Refractory Glaucoma1
Not AvailableCompletedTreatmentAdhesive Capsulitis1
Not AvailableCompletedTreatmentAlopecia Areata (AA)3
Not AvailableCompletedTreatmentBack Pain1
Not AvailableCompletedTreatmentBursitis1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS) / Pain, Chronic1
Not AvailableCompletedTreatmentCataracts1
Not AvailableCompletedTreatmentDiabetic Macular Edema (DME)2
Not AvailableCompletedTreatmentHidradenitis Suppurativa (HS)1
Not AvailableCompletedTreatmentKeloid Ear1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentLateral Epicondylitis1
Not AvailableCompletedTreatmentMigraines1
Not AvailableCompletedTreatmentOsteoarthritis (OA)1
Not AvailableCompletedTreatmentRotator Cuff Disease1
Not AvailableCompletedTreatmentSacroiliitis1
Not AvailableCompletedTreatmentShoulder Pain / Subacromial Bursitis1
Not AvailableCompletedTreatmentShoulder Pain / Subacromial Bursitis / Subdeltoid Bursitis1
Not AvailableCompletedTreatmentSubacromial Bursitis1
Not AvailableCompletedTreatmentTrigger Finger1
Not AvailableCompletedTreatmentOcular inflammatory conditions1
Not AvailableRecruitingDiagnosticCarpal Tunnel1
Not AvailableRecruitingTreatmentCarpal Tunnel Syndrome (CTS)2
Not AvailableRecruitingTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableRecruitingTreatmentPancreatitis / Pancreatitis, Chronic1
Not AvailableRecruitingTreatmentPelvic Pain1
Not AvailableTerminatedTreatmentDermatitis, Eczematous1
Not AvailableTerminatedTreatmentLegg-Calve Perthes Disease1
Not AvailableTerminatedTreatmentLumbar and Other Intervertebral Disc Disorders With Radiculopathy1
Not AvailableTerminatedTreatmentOral Lichen Planus1
Not AvailableUnknown StatusTreatmentAcne Keloidalis / AK / AKN / Dermatitis Papillaris Capillitii / Folliculitis Keloidalis Nuchae / Folliculitis Nuchae Scleroticans / Lichen Keloidalis Nuchae / NdYag Laser / Sycosis Framboesiformis1
Not AvailableUnknown StatusTreatmentAlopecia Areata (AA)1
Not AvailableUnknown StatusTreatmentGlaucoma1
Not AvailableUnknown StatusTreatmentRheumatoid Arthritis1
Not AvailableUnknown StatusTreatmentThyroid Diseases1
Not AvailableWithdrawnHealth Services ResearchAtopic Dermatitis (AD)1
Not AvailableWithdrawnTreatmentAdhesive Capsulitis1
Not AvailableWithdrawnTreatmentMacular Degeneration1
Not AvailableWithdrawnTreatmentNeovascular Age-Related Macular Degeneration1
Not AvailableWithdrawnTreatmentSubacromial Bursitis / Subacromial Impingement Syndrome1

Pharmacoeconomics

Manufacturers
  • Astellas pharma us inc
  • Bristol myers squibb co
  • Barr laboratories inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Abbott laboratories
  • Sanofi aventis us llc
  • Ivax pharmaceuticals inc
  • Apothecon inc div bristol myers squibb
  • Solvay pharmaceuticals
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Altana inc
  • Ambix laboratories div organics corp america
  • G and w laboratories inc
  • Morton grove pharmaceuticals inc
  • Perrigo new york inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Taro pharmaceuticals inc
  • Taro pharmaceuticals usa inc
  • Topiderm inc
  • Vintage pharmaceuticals llc
  • Del ray laboratories inc
  • Savage laboratories inc div altana inc
  • Parnell pharmaceuticals inc
  • Sandoz canada inc
  • Allergan inc
  • Alcon inc
  • Bristol myers squibb co pharmaceutical research institute
  • Wockhardt eu operations (swiss) ag
  • Carolina medical products co
  • Lyne laboratories inc
  • Lupin atlantis holding sa switzerland
  • Ranbaxy laboratories inc
  • Akorn inc
Packagers
Dosage forms
FormRouteStrength
Spray, meteredNasal.5 mg/mL
SyrupOral.4 mg
CreamTopical0.5 %
CreamTopical5 mg
CreamTopical.025 %
CreamTopical.25 mg
LiquidIntra-articular; Intramuscular; Intrasynovial40 mg
LiquidIntra-articular; Intradermal; Intramuscular25 mg
CreamTopical1 mg
OintmentTopical.1 %
SyrupOral2 mg
TabletOral2 mg
TabletOral4 mg
Injection, suspensionIntra-articular; Parenteral20 mg/mL
Injection, suspensionIntralesional; Parenteral5 mg/mL
SuspensionIntra-articular20 mg
Aerosol, meteredRespiratory (inhalation)200 mcg
Kit
PasteDental1 mg
OintmentTopical1 mg
Injection, suspensionIntra-articular; Intralesional10 mg/mL
SuspensionIntra-articular; Intrabursal; Intradermal; Intrasynovial10 mg
Injection, suspensionIntra-articular; Intramuscular40 mg/mL
Injection, suspensionIntramuscular40 mg/mL
Injection, suspensionIntramuscular40 mg/1
SuspensionIntra-articular; Intramuscular40 mg
Aerosol, meteredNasal100 mcg
Spray, meteredNasal55 mcg
CreamTopical
OintmentTopical
PasteDental.1 %
Kit
KitInfiltration; Intra-articular; Intramuscular; Respiratory (inhalation); Topical
Injection, solutionIntra-articular; Intramuscular40 mg/mL
KitEpidural; Infiltration; Intra-articular; Intramuscular; Topical
SuspensionIntramuscular40 mg
CreamTopical0.1 %
OintmentTopical0.25 mg
OintmentTopical0.1 %
Aerosol, sprayTopical.147 mg/g
CreamTopical.025 mg/g
CreamTopical.25 mg/g
CreamTopical1 mg/g
CreamTopical1 mg/1
CreamTopical5 mg/g
Injection, suspensionIntra-articular; Intrabursal; Intradermal; Intralesional10 mg/mL
LotionTopical.25 mg/mL
LotionTopical1 mg/mL
OintmentTopical.25 mg/g
OintmentTopical.5 mg/g
OintmentTopical1 mg/g
OintmentTopical5 mg/g
PasteDental1 mg/g
PasteTopical1 mg/g
SprayTopical.147 mg/g
Spray, meteredNasal55 ug/1
SuspensionIntra-articular; Intrabursal; Intramuscular40 mg
SuspensionIntralesional40 mg
SuspensionIntra-articular; Intradermal; Intralesional; Intramuscular40 mg
Injection, suspensionOphthalmic40 mg/mL
SuspensionIntravitreal40 mg
Prices
Unit descriptionCostUnit
Triesence 40 mg/ml vial148.8USD ml
Kenalog Aerosol 63 gm Can118.99USD can
Nasacort AQ 55 mcg/act Aerosol (Nasal Spray)118.74USD inhaler
Triamcinolone Acetonide 0.1% Paste 5 gm Tube71.7USD tube
Kenalog 0.5% Cream 20 gm Tube54.99USD tube
Kenalog 0.1% Lotion 60ml Bottle51.99USD bottle
Kenalog 0.025% Lotion 60ml Bottle46.99USD bottle
Triamcinolone Acetonide 0.025% Lotion 60ml Bottle40.99USD bottle
Triamcinolone diacetate powder26.01USD g
Triamcinolone powder20.29USD g
Kenalog 0.1% Cream 15 gm Tube18.99USD tube
Triamcinolone Acetonide 0.1% Ointment 80 gm Tube18.99USD tube
Triamcinolone Acetonide 0.5% Ointment 15 gm Tube14.99USD tube
Aristospan 20 mg/ml vial14.19USD ml
Oralone 0.1% paste13.57USD g
Triamcinolone Acetonide 0.025% Cream 80 gm Tube12.99USD tube
Triamcinolone Acetonide 0.1% Cream 80 gm Tube12.99USD tube
Triamcinolone Acetonide 0.5% Cream 15 gm Tube12.99USD tube
Triamcinolone Acetonide 0.025% Cream 15 gm Tube11.99USD tube
Triamcinolone Acetonide 0.025% Ointment 80 gm Tube11.99USD tube
Triamcinolone Acetonide 0.1% Cream 15 gm Tube11.99USD tube
Triamcinolone Acetonide 0.1% Ointment 15 gm Tube11.99USD tube
Kenalog-40 40 mg/ml vial8.99USD ml
Triamcinolone acet 40 mg/ml sus8.42USD ml
Kenalog-40 40 mg/ml7.53USD ml
Nasacort aq nasal spray6.99USD g
Triamcinolone 0.1% paste6.4USD g
Triamcinolone Acetonide 40 mg/ml6.29USD ml
Triamcinolone Acetonide Usp 40 mg/ml5.76USD ml
Aristospan 5 mg/ml vial3.54USD ml
Kenalog-10 10 mg/ml3.24USD ml
Triamcinolone Acetonide 10 mg/ml2.71USD ml
Kenalog-10 10 mg/ml vial2.32USD ml
Triamcinolone acet 10 mg/ml sus2.18USD ml
Aristocort C 0.5 % Cream1.3USD g
Oracort 0.1 % Paste1.19USD g
Triderm 0.1% cream0.47USD g
Triamcinolone 0.5% cream0.22USD g
Aristocort R 0.1 % Cream0.15USD g
Aristocort R 0.1 % Ointment0.15USD g
Triamcinolone Acetonide 0.1% Cream0.07USD gm
Triaderm Regular 0.1 % Cream0.07USD g
Triamcinolone 0.025% cream0.06USD g
Triamcinolone Acetonide 0.1% Ointment0.05USD gm
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2268927No2003-09-232017-07-02Canada
US5976573No1996-07-032016-07-03Us
US6143329No1996-07-032016-07-03Us
US7977045No1996-07-032016-07-03Us
US6395294No2000-01-132020-01-13Us
US8211880No2009-03-102029-03-10Us
US8128960No2009-12-172029-12-17Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)270 °CPhysProp
water solubility80 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.16HANSCH,C ET AL. (1995)
logS-3.69ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.847 mg/mLALOGPS
logP0.84ALOGPS
logP0.24ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)11.75ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area115.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity99.38 m3·mol-1ChemAxon
Polarizability39.79 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9823
Blood Brain Barrier+0.9528
Caco-2 permeable+0.7397
P-glycoprotein substrateSubstrate0.8204
P-glycoprotein inhibitor INon-inhibitor0.8759
P-glycoprotein inhibitor IINon-inhibitor0.9725
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8858
CYP450 2D6 substrateNon-substrate0.9006
CYP450 3A4 substrateSubstrate0.7049
CYP450 1A2 substrateNon-inhibitor0.9144
CYP450 2C9 inhibitorNon-inhibitor0.8939
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.911
CYP450 3A4 inhibitorNon-inhibitor0.9007
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.942
Ames testNon AMES toxic0.8858
CarcinogenicityNon-carcinogens0.9521
BiodegradationNot ready biodegradable0.9952
Rat acute toxicity2.3369 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9562
hERG inhibition (predictor II)Inhibitor0.6125
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.24 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-00di-2931000000-ee37afbf8c285181a340
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006t-3970000000-70c8dcf068945a18ecdd
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 16-alpha-hydroxysteroids / 17-hydroxysteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones
show 10 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / 17-hydroxysteroid / 16-hydroxysteroid / 11-hydroxysteroid
show 26 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 3-oxo Delta(4)-steroid, 20-oxo steroid, fluorinated steroid, 16alpha-hydroxy steroid, 21-hydroxy steroid, C21-steroid hormone (CHEBI:9667)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL: Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009 Sep 10;2:58. doi: 10.1186/1755-8794-2-58. [PubMed:19744340]
  2. Issar M, Sahasranaman S, Buchwald P, Hochhaus G: Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J. 2006 Mar;27(3):511-6. [PubMed:16507850]
  3. Shahin V, Ludwig Y, Schafer C, Nikova D, Oberleithner H: Glucocorticoids remodel nuclear envelope structure and permeability. J Cell Sci. 2005 Jul 1;118(Pt 13):2881-9. [PubMed:15976447]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dort K, Padia S, Wispelwey B, Moore CC: Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009 Jun 8;6:10. doi: 10.1186/1742-6405-6-10. [PubMed:19505306]
  2. Hagan JB, Erickson D, Singh RJ: Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. Pain Med. 2010 Jul;11(7):1132-5. doi: 10.1111/j.1526-4637.2010.00852.x. Epub 2010 Apr 29. [PubMed:20456080]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Schaefer EC, Stewart AA, Durgam SS, Byron CR, Stewart MC: Effects of sodium hyaluronate and triamcinolone acetonide on glucosaminoglycan metabolism in equine articular chondrocytes treated with interleukin-1. Am J Vet Res. 2009 Dec;70(12):1494-501. doi: 10.2460/ajvr.70.12.1494. [PubMed:19951121]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Ehrich M, Jortner BS, Gross WB: Types of adrenocorticoids and their effect on organophosphorus-induced delayed neuropathy in chickens. Toxicol Appl Pharmacol. 1988 Feb;92(2):214-23. [PubMed:3341034]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Groyer A, Le Bouc Y, Joab I, Radanyi C, Renoir JM, Robel P, Baulieu EE: Chick oviduct glucocorticosteroid receptor. Specific binding of the synthetic steroid RU 486 and immunological studies with antibodies to chick oviduct progesterone receptor. Eur J Biochem. 1985 Jun 3;149(2):445-51. [PubMed:3996417]
  4. Svec F, Harrison RW: Conditions affecting AtT-20 cell glucocorticoid uptake. Steroids. 1981 Feb;37(2):143-56. [PubMed:7222146]
  5. Eisen HJ: An antiserum to the rat liver glucocorticoid receptor. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3893-7. [PubMed:7001446]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34